ZA200708106B - Novel C-17 -heteroaryl steroidal CYP17 inhibitors/anti-androgens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity - Google Patents

Novel C-17 -heteroaryl steroidal CYP17 inhibitors/anti-androgens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

Info

Publication number
ZA200708106B
ZA200708106B ZA200708106A ZA200708106A ZA200708106B ZA 200708106 B ZA200708106 B ZA 200708106B ZA 200708106 A ZA200708106 A ZA 200708106A ZA 200708106 A ZA200708106 A ZA 200708106A ZA 200708106 B ZA200708106 B ZA 200708106B
Authority
ZA
South Africa
Prior art keywords
synthesis
androgens
pharmacokinetics
novel
biological activities
Prior art date
Application number
ZA200708106A
Other languages
English (en)
Inventor
Brodie Angela
Njar Vincent
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of ZA200708106B publication Critical patent/ZA200708106B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200708106A 2005-03-02 2007-09-20 Novel C-17 -heteroaryl steroidal CYP17 inhibitors/anti-androgens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity ZA200708106B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02

Publications (1)

Publication Number Publication Date
ZA200708106B true ZA200708106B (en) 2008-12-31

Family

ID=36941503

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708106A ZA200708106B (en) 2005-03-02 2007-09-20 Novel C-17 -heteroaryl steroidal CYP17 inhibitors/anti-androgens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

Country Status (22)

Country Link
US (1) US7875599B2 (bg)
EP (2) EP1853619B1 (bg)
JP (2) JP5130453B2 (bg)
KR (1) KR101380959B1 (bg)
CN (2) CN101155823A (bg)
AT (1) ATE482969T1 (bg)
AU (1) AU2006218711B2 (bg)
BR (1) BRPI0607523A2 (bg)
CA (1) CA2599953C (bg)
DE (1) DE602006017175D1 (bg)
DK (2) DK2206719T3 (bg)
EA (1) EA019560B1 (bg)
ES (2) ES2528055T3 (bg)
HK (1) HK1115387A1 (bg)
IL (3) IL185608A (bg)
MX (1) MX2007010593A (bg)
NZ (1) NZ561571A (bg)
PL (2) PL1853619T3 (bg)
PT (2) PT1853619E (bg)
SI (2) SI2206719T1 (bg)
WO (1) WO2006093993A1 (bg)
ZA (1) ZA200708106B (bg)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
WO2006093993A1 (en) 2005-03-02 2006-09-08 University Of Maryland Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
EP2167090A4 (en) 2007-06-06 2010-08-25 Univ Maryland HDAC INHIBITORS AND HORMONE TREATMENT MEDICAMENTS
WO2009114658A2 (en) * 2008-03-12 2009-09-17 University Of Maryland, Baltimore Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
US20100048912A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110118219A1 (en) * 2008-03-25 2011-05-19 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
WO2009129208A2 (en) * 2008-04-14 2009-10-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress reponse
WO2010024930A2 (en) 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
BRPI0920681A2 (pt) * 2008-10-28 2015-12-29 Biomarin Pharm Inc inibidores de decahidro-1h-indenoquinolinona e decahidro-3h-ciclopentafenantridinona de cyp17
BRPI1008745A2 (pt) 2009-02-05 2019-09-17 Tokai Pharmaceuticals Inc pró-fármacos de inibidores esteroidais de cyp17/antiandrogênios
GB2479693B (en) * 2009-02-05 2014-04-09 Tokai Pharmaceuticals Inc Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
GB2514957A (en) * 2009-02-05 2014-12-10 Tokai Pharmaceuticals Inc Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
EA021011B1 (ru) 2009-06-26 2015-03-31 Новартис Аг 1,3-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ИМИДАЗОЛИДИН-2-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ Cyp 17
WO2011017534A2 (en) * 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
EP2499151A4 (en) * 2009-11-13 2013-03-20 Tokai Pharmaceuticals Inc MAMMALIAN STEROID METABOLITES
CA2782266A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
TW201307378A (zh) * 2010-12-16 2013-02-16 Biomarin Pharm Inc Ｃｙｐ１１ｂ、ｃｙｐ１７及／或ｃｙｐ２１抑制劑
EA023064B1 (ru) 2011-04-28 2016-04-29 Новартис Аг ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ，インク． 前立腺癌を処置するための新規な組成物及び方法
CA2859986A1 (en) * 2011-12-22 2013-06-27 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using pi3k/mtor inhibitors
EP2968370A4 (en) 2013-03-14 2016-09-21 Univ Maryland AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
EP2991644B1 (en) 2013-04-04 2020-03-25 University of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
AU2014306698A1 (en) * 2013-08-12 2016-01-28 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
ES2709480T3 (es) 2013-12-24 2019-04-16 Harvard College Análogos de cortistatina y síntesis y usos de los mismos
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
WO2016119742A1 (zh) * 2015-01-29 2016-08-04 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2017066697A1 (en) 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
ES2700901B2 (es) * 2016-08-08 2019-08-06 Ind Chimica Srl Proceso para la preparación de 3ß-hidroxi-17-(1h-benzimidazol-1-il)androsta-5,16-dieno.
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
US20210054020A1 (en) * 2018-02-13 2021-02-25 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use
CA3089588A1 (en) * 2018-02-13 2019-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (bg) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) * 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
NZ543612A (en) 2003-07-29 2008-03-28 Dompe Spa Pharmaceutical combination of G-CSF and PLGF useful for blood stem cell
WO2006093993A1 (en) * 2005-03-02 2006-09-08 University Of Maryland Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

Also Published As

Publication number Publication date
US20080280864A1 (en) 2008-11-13
SI1853619T1 (sl) 2011-01-31
JP2008536807A (ja) 2008-09-11
EP2206719A3 (en) 2011-01-05
IL210480A (en) 2015-06-30
SI2206719T1 (sl) 2015-03-31
PT2206719E (pt) 2015-02-05
CA2599953A1 (en) 2006-09-08
ES2353413T3 (es) 2011-03-01
CN103349664A (zh) 2013-10-16
EP2206719A2 (en) 2010-07-14
KR101380959B1 (ko) 2014-04-04
BRPI0607523A2 (pt) 2009-09-08
HK1115387A1 (bg) 2008-11-28
CN101155823A (zh) 2008-04-02
NZ561571A (en) 2009-09-25
JP2012255026A (ja) 2012-12-27
EP1853619A4 (en) 2009-08-26
EA200701872A1 (ru) 2008-06-30
AU2006218711A1 (en) 2006-09-08
JP5130453B2 (ja) 2013-01-30
DE602006017175D1 (de) 2010-11-11
DK1853619T3 (da) 2011-01-10
CA2599953C (en) 2013-08-13
MX2007010593A (es) 2008-02-20
IL210480A0 (en) 2011-03-31
EA019560B1 (ru) 2014-04-30
IL210478A0 (en) 2011-03-31
ES2528055T3 (es) 2015-02-03
ATE482969T1 (de) 2010-10-15
US7875599B2 (en) 2011-01-25
JP5613206B2 (ja) 2014-10-22
AU2006218711A2 (en) 2006-09-08
EP1853619B1 (en) 2010-09-29
IL185608A (en) 2016-06-30
EP2206719B1 (en) 2014-10-22
PL2206719T3 (pl) 2015-03-31
AU2006218711B2 (en) 2010-11-11
EP1853619A1 (en) 2007-11-14
IL185608A0 (en) 2008-01-06
WO2006093993A1 (en) 2006-09-08
PL1853619T3 (pl) 2011-03-31
PT1853619E (pt) 2011-01-03
DK2206719T3 (en) 2015-01-26
KR20070120119A (ko) 2007-12-21

Similar Documents

Publication Publication Date Title
ZA200708106B (en) Novel C-17 -heteroaryl steroidal CYP17 inhibitors/anti-androgens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
GB2470700A (en) Novel prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogans: synthesis, in vitro biological activities, Pharmacokinetics and antitumor activity
AU2010210422A8 (en) Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
WO2006044379A3 (en) Novel curcumin analogues and uses thereof
HRP20150437T1 (en) Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
EA017278B9 (ru) Соединения азаиндазола и способы применения
HK1061354A1 (en) Synthesis of 4-amino-thalidomide enantiomers
WO2003088927A3 (en) Novel curcumin analogues and uses thereof
EP2966065A3 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
PT1928882E (pt) (s)-n-metilnaltrexona, processo para a sua síntese e sua utilização farmacêutica
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2006052889A3 (en) Quinolinone-carboxamide compounds
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
TW200612925A (en) Prodrug substituted benzoxazoles as estrogenic agents
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
GB2453402A (en) Bis-pyyrolo[2.1.-c] benzodiazepine-anthraquinone conjugates as antitumour agents and a process for the preparation thereof
WO2006034478A3 (en) Isomigrastatin analogs in the treatment of cancer
CY1115910T1 (el) ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE
TW200603812A (en) D-homo-17-chlor-16(17)-ene steroids